Propanc Biopharma PPCB
NASDAQ PPCB
$0.32 0.00 (-0.31%)
As of: Oct 21, 2026 · 10:05 AM EDT

Propanc Biopharma (PPCB) Preferred Stock Liabilities (2025)

Updated

Propanc Biopharma's Preferred Stock Liabilities was $1 million in fiscal Q2 2026 (quarter ended Dec 31, 2025).

Analysis

Propanc Biopharma (PPCB) Preferred Stock Liabilities (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,129.39 Bn 1,097.98 Bn 19.71 Bn -
2 Johnson & Johnson 615.68 Bn 534.21 Bn 17.26 Bn -
3 AbbVie 505.77 Bn 478.89 Bn 12.70 Bn -
4 Merck 366.50 Bn 320.88 Bn 12.21 Bn -
5 Novartis Ag 297.33 Bn 261.32 Bn 11.24 Bn -
6 Astrazeneca 261.02 Bn 234.71 Bn 12.86 Bn -
7 Amgen 235.47 Bn 190.87 Bn 7.24 Bn -
8 Gilead Sciences 189.20 Bn 163.40 Bn 6.22 Bn -
9 Pfizer 170.20 Bn 116.85 Bn 10.94 Bn -
10 Propanc Biopharma 359,586.87 -1.65 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1.00 Mn
API Access

Propanc Biopharma Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=PPCB&period=max&api_key=YOUR_API_KEY